Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 7/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.47 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8255448 | 1.00 | L3MBTL3 (0.47) | L3MBTL3L3MBTL1MBTD1HRH3CYP2C19 | |
| SCHEMBL8263855 | 1.00 | L3MBTL3 (0.47) | L3MBTL3L3MBTL1MBTD1HRH3CYP2C19 | |
| SCHEMBL8259607 | 0.98 | L3MBTL3 (0.46) | L3MBTL3L3MBTL1MBTD1HRH3CYP2C19 | |
| SCHEMBL3439846 | 0.98 | L3MBTL3 (0.48) | L3MBTL3L3MBTL1MBTD1HRH3CYP2C19 | |
| SCHEMBL10162401 | 0.93 | L3MBTL3 (0.44) | L3MBTL3L3MBTL1MBTD1HRH3 | |
| SCHEMBL25050072 | 0.91 | L3MBTL3 (0.44) | L3MBTL3L3MBTL1MBTD1HRH3 | |
| SCHEMBL10162384 | 0.90 | HRH3 (0.46) | L3MBTL3L3MBTL1MBTD1HRH3 | |
| SCHEMBL22456360 | 0.89 | L3MBTL3 (0.42) | L3MBTL3L3MBTL1MBTD1HRH3CYP2C19 | |
| SCHEMBL24870608 | 0.89 | HRH3 (0.44) | L3MBTL3L3MBTL1MBTD1HRH3 | |
| SCHEMBL10162381 | 0.87 | HRH3 (0.43) | L3MBTL3L3MBTL1MBTD1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240209363-A1 | OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-06-27 | — | — | US | disclosed |
| US-11911403-B2 | Antisense-induced exon exclusion in type VII collagen | SAREPTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11911403-B2 | Antisense-induced exon exclusion in type VII collagen | SAREPTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11827641-B2 | Toll-like receptor antagonist compounds and methods of use | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| EP-4279486-A1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | Guangzhou Salustier Biosciences Co., Ltd. (CN) | 2023-11-22 | — | — | EP | disclosed |
| US-11802132-B2 | Small molecules for inducing selective protein degradation and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11802132-B2 | Small molecules for inducing selective protein degradation and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-11760741-B2 | Pro-drugs of eliglustat | KASHIV BIOSCIENCES, LLC (US) | 2023-09-19 | — | — | US | disclosed |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
| US-7173129-B2 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | ATHERO GENICS, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20070004764-A1 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
| US-20070004764-A1 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
| US-20050085506-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION AND PHARMACOPEIA, INC. | 2005-04-21 | — | — | US | disclosed |
| US-20040229902-A1 | Bridged N-arylsulfonylpiperidines as gamma-secretase inhibitors | SCHERING CORPORATION | 2004-11-18 | — | — | US | disclosed |
| US-20040171614-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION | 2004-09-02 | — | — | US | disclosed |
| US-20040097560-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | THE PROCTER & GAMBLE COMPANY | 2004-05-20 | — | — | US | disclosed |
| US-20040097559-A1 | N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones | WARNER CHILCOTT COMPANY, LLC | 2004-05-20 | — | — | US | disclosed |
| US-20040097559-A1 | N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones | WARNER CHILCOTT COMPANY, LLC | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | L3MBTL3 3443/4885L3MBTL1 2469/4885MBTD1 1717/4885 |
| US-20040097559-A1 | N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones | IL17A, TLR1, CYP51A1 | L3MBTL3 3621/4885L3MBTL1 2517/4885MBTD1 3043/4885 |
| US-20040171614-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | L3MBTL3 3906/4885L3MBTL1 4015/4885MBTD1 4148/4885 |
| US-20240209363-A1 | OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES | HTT, UPF1, TARDBP | L3MBTL3 87/4885L3MBTL1 112/4885MBTD1 1690/4885 |
| US-20040097560-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | IL17A, CYP51A1, CD4 | L3MBTL3 3215/4885L3MBTL1 2289/4885MBTD1 3065/4885 |
| US-11827641-B2 | Toll-like receptor antagonist compounds and methods of use | TLR7, TLR9, TLR1 | L3MBTL3 3781/4885L3MBTL1 3165/4885MBTD1 1376/4885 |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | TNNI3, IDH2, GLS | L3MBTL3 2147/4885L3MBTL1 2667/4885MBTD1 2952/4885 |
| US-11760741-B2 | Pro-drugs of eliglustat | GCG, GLP1R, PROKR1 | L3MBTL3 4809/4885L3MBTL1 4774/4885MBTD1 2914/4885 |
| US-20070004764-A1 | Nitrogen-containing aromatic derivatives | NR0B2, NR0B1, NR4A1 | L3MBTL3 2896/4885L3MBTL1 2633/4885MBTD1 3942/4885 |
| US-20050085506-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | L3MBTL3 2301/4885L3MBTL1 2500/4885MBTD1 3916/4885 |
| US-11802132-B2 | Small molecules for inducing selective protein degradation and uses thereof | BAZ2A, BRD3, BRPF3 | L3MBTL3 1793/4885L3MBTL1 2030/4885MBTD1 217/4885 |
| US-11911403-B2 | Antisense-induced exon exclusion in type VII collagen | COL2A1, COL14A1, COL1A1 | L3MBTL3 626/4885L3MBTL1 304/4885MBTD1 2489/4885 |
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | KDM1A, TET1, KDM3A | L3MBTL3 2443/4885L3MBTL1 1082/4885MBTD1 2806/4885 |
| US-20040229902-A1 | Bridged N-arylsulfonylpiperidines as gamma-secretase inhibitors | BACE1, BACE2, PSEN1 | L3MBTL3 4609/4885L3MBTL1 4095/4885MBTD1 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.